CareLit Fachartikel

PSMA-ligand PET allows a more accurate therapeutic response evaluation of bone metastases in prostate cancer compared to computed tomography

Viktor Fech, Ian Alberts, Axel Rominger, Ali Afshar-Oromieh · Nuklearmedizin - NuclearMedicine · 2019 · Heft 04 · S. 331-332

Dokument
976725
CareLit-ID
Jahr
2019
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Nuklearmedizin - NuclearMedicine
Autor:innen
Viktor Fech, Ian Alberts, Axel Rominger, Ali Afshar-Oromieh
Ausgabe
Heft 04 / 2019
Jahrgang 58
Seiten
331-332
Erschienen: 2019-08-01 00:00:00
ISSN
0029-5566
DOI
10.1055/a-0895-5078

Zusammenfassung

AbstractA patient with bone metastases of prostate cancer was referred for 68Ga-PSMA-11 PET/CT. Compared to a 68Ga-PSMA-11 PET/CT four months previously, the CT-component of the current PET/CT showed morphological progress in all lesions despite continuous therapy with docetaxel and denosumab. Contrarily, the PET-component showed a reduction of tracer-uptake, which correlated with PSA decrease between the two PET/CT-scans (16.2 ng/ml vs. 3.1 ng/ml). This case highlights 68Ga-PSMA-11 PET/CT as a promising tool for therapy monitoring of prostate cancer and could serve as a basis for a novel monitoring strategy. Vo…

Schlagworte

68Ga–PSMA-11 PSMA PET/CT bone metastases prostate cancer therapy monitoring Nuklearmedizin - NuclearMedicine